CHICAGO HIGHLIGHTS 2024 – LUNG ROUNDTABLE DISCUSSION: ADRIATIC
OR
Chair
Dr. Barb Melosky
Panelists
Dr. Rosalyn Juergens
Dr. Peter Ellis
This program has been made possible through unrestricted support from Pfizer
Studies/trials discussed:
- ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
- S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
